Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw strong trading volume on Wednesday . 1,311,128 shares were traded during mid-day trading, an increase of 112% from the previous session’s volume of 618,339 shares.The stock last traded at $4.24 and had previously closed at $3.77.

Several research analysts have recently issued reports on the company. FBR & Co restated a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, June 1st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Finally, Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.70.

The stock’s market cap is $296.98 million. The stock’s 50 day moving average is $3.05 and its 200-day moving average is $3.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.08. During the same quarter in the previous year, the business earned ($0.21) earnings per share. The firm had revenue of $4.82 million for the quarter, compared to the consensus estimate of $5.42 million. BioCryst Pharmaceuticals’s quarterly revenue was down 29.4% on a year-over-year basis. On average, analysts forecast that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.

Several institutional investors recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares during the period. Globeflex Capital L P bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $1,241,000. Finally, Jennison Associates LLC boosted its position in BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the period.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.